Q4 2025 Globus Medical Inc Earnings Call Transcript
Key Points
- Globus Medical Inc (GMED) reported record Q4 performance with revenue totaling $826.4 million, growing 25.7% compared to the prior year quarter.
- The US Spine business showed strong growth, achieving 10% growth in Q4 and maintaining momentum into the first quarter of 2026.
- Enabling Technologies sales grew 18.5% year-over-year, driven by increased sales of EGPS systems and successful pipeline deal closures.
- The Trauma business delivered approximately 27% growth in Q4, driven by uptake of legacy trauma line and precise limb-lengthening products.
- The Nevro acquisition was accretive to earnings within the first nine months post-acquisition, ahead of initial guidance by 15 months.
- International revenue growth was impacted by supply chain shortages, particularly in the APAC region, which posed challenges throughout the year.
- The Nevro business may experience short-term lumpiness as it stabilizes post-acquisition, potentially affecting consistent growth.
- Operating leases for Enabling Technologies may result in less immediate revenue recognition, impacting short-term sales figures.
- The company faces competitive pressures in the spine market, with new robotic navigation systems being introduced by competitors.
- Cash, cash equivalents, and marketable securities decreased to $629.1 million from $956.2 million due to debt repayment, acquisitions, and share repurchases.
Welcome to Globus Medical's fourth quarter and full year 2025 earnings call. (Operator Instructions)
I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.
Thank you, Dana, and thank you, everyone, for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and CEO; and Kyle Kline, Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2025 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
